According to filings with the U.S. Securities and Exchange Commission, Khartis Therapeutics has raised $95 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Forge Life Science Partners, Longwood Fund, Alexandria Venture Investments, Foresite Capital, Lilly Asia Ventures, and Nextech Invest

About Khartis Therapeutics
Khartis is a biotechnology company developing first- and best-in-class oral small molecule medicines targeting clinically validated immunology pathways. The companys lead program is the first oral, selective IGF-1R inhibitor designed for the treatment of thyroid eye disease (TED). Khartis was originally incubated within Foresite Labs and is backed by leading life sciences investors including Foresite Capital, Lilly Asia Ventures, Nextech Invest, Forge Life Science Partners, Longwood Fund and Alexandria Venture Investments. Khartis is headquartered in San Diego, California.

To learn more, visit https://khartis.com/
Linkedin: https://www.linkedin.com/company/khartis-therapeutics-inc/

Contact:
Robert Hoffman, Chief Executive Officer
https://www.linkedin.com/in/robert-hoffman-b576946/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.